Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2005-03-08
2005-03-08
Housel, James (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007230, C435S007240, C435S029000, C435S041000, C435S372100, C435S373000
Reexamination Certificate
active
06864047
ABSTRACT:
Diagnostic methods for the detection of multiple myeloma (MM) and the identification of high-risk patients with multiple myeloma-related plasma proliferative disorders, such as MGUS or SMM, likely to progress to active MM are described. The diagnosis is based on the determination of concentrations of bioactive IL-1β produced by the bone marrow plasma cells of these patients. Also described are therapeutic methods for the treatment of MM and for the chemoprevention of the progression from disorders such as MGUS and SMM to active MM, involving the administration of inhibitors of IL-1β.
REFERENCES:
patent: 5470952 (1995-11-01), Stahl et al.
Donovan 1998 Leukemia vol. 12, pp. 593-600.*
Carter 1990 Br Journal of Haematology vol 74, pp. 424-431.*
Carter ,1990 British Journal of Haematology 74: 424-431.*
Klein ,Blood 1989 vol. 73 pp. 517-526.*
Thomas et al., “Interdependence Between Cytokines and Cell Adhesion Molecules to Induce Interleukin-6 Production by Stromal Cells in Myeloma,” Leukemia and Lymphoma, vol. 32(1-2), pp. 107-119, 1998.
Choi et al., “Macrophage Inflammatory Protein 1-Alpha is a Potential Osteoclast Stimulatory Factor in Multiple Myeloma,” Blood, vol. 96, No. 2, pp. 671-675, Jul. 15, 2000.
Schindler et al., “Dissociation Between Interleukin-1β mRNA and Protein Synthesis in Human Peripheral Blood Mononuclear Cells,” The Journal of Biological Chemistry, vol. 265, No. 18, pp. 10232-10237, Jun. 25, 1990.
Chauhan et al. “Multiple Myeloma Cell Adhesion-Induced Interleukin-6 Expression in Bone Marrow Stromal Cells Involves Activation of NF-kB,” Blood, vol. 87, No. 3, pp. 1104-1112, Feb. 1, 1996.
Lust et al., “Biology of the Transition of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma,” Cancer Control, Journal of the Moffitt Cancer Center, vol. 5, No. 3, pp. Cover Sheet, 203, and 209-217, May/Jun. 1998.
Borset et al., “Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation,”Br. J. Haematol., 1993, 85:446-451.
Kiss et al., “Determination of IL6, IL1, and IL4 in the Plasma of Patients with Multiple Myeloma,”Leukemia and Lymphoma, 1994, Harwood Academic Publishers GmbH, vol. 14, pp. 335-340.
Klein et al., “Paracrine Rather Than Autocrine Regulation of Myeloma-Cell Growth and Differentiation by Interleukin-6,”Blood, 1989, 73(2):517-526.
Sati et al., “Expression of interleukin-1β and tumuor necrosis factor-α in plasma cells from patients with multiple myeloma,”Br. J. Haematol., 1999, 104:350-357.
Alexanian and Dimopoulos, “The Treatment of Multiple Myeloma,”New Engl. J. Med., 1994, 330(7):484-489.
Balkwill (ed.),Cytokines—A Practical Approach, 1991, IRL Press at Oxford University Press, Oxford, pp. 311-312.
Bataille et al., “Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias,”J. Clin. Invest., 1989, 84:2008-2011.
Bataille et al., “Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma,”Blood, 1995, 86(2):685-691.
Carter et al., “The role of interleukin-1 and tumour necrosis factor-α in human multiple myeloma,”Br. J. Haematol., 1990, 74:424-431.
Carter et al., “Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein,”Nature, 1990, 344:633-638.
Costes et al., “Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production,”Br. J. Haematol., 1998, 103:1152-1160.
Dinarello et al., “Anticytokine Strategies in the Treatment of the Systemic Inflammatory Resposne Syndrome,”JAMA, 1993, 269(14):1829-1835.
Dinarello, “Biologic Basis for Interleukin-1 in Disease,”Blood, 1996, 87(6):2095-2147.
Dinarello and Thompson, “Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro,”Immunol. Today, 1991, 12(11):404-410.
Donovan et al., “Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma,”Leukemia, 1998, 12:593-600.
Eisenberg et al., “Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist,”Nature, 1990, 343:341-346.
Greipp and Lust, “Pathogenetic Relation Between Monoclonal Gammopathies of Undetermined Significance and Multiple Myeloma,”Stem Cells, 1995, 13(Suppl. 2):10-21.
Greipp and Witzig, “Biology and treatment of myeloma,”Curr. Opn. Oncol., 1996, 8:20-27.
Grigorieva et al., “The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone,”Exp. Hematol., 1998, 26:597-603.
Hannum et al., “Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor,”Nature, 1990, 343:336-340.
Hawley et al., “Expression of Retrovirally Transduced IL-1α in IL-6-Dependent B Cells: A Murine Model of Aggressive Multiple Myeloma,”Growth Factors, 1991, 5:327-338.
Hilbert et al., “Interleukin 6 Is Essential for In Vivo Development of B Lineage Neoplasms,”J. Exp. Med., 1995, 182:243-248.
Howard et al., “IL-1-Converting Enzyme Requires Aspartic Acid Residues for Processing of the IL-1β Precursor at Two Distinct Sites and Does Not Cleave 31-kDa IL-1α,”J. Immunol., 1991, 147(9):2964-2969.
Kawano et al., “Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas,”Nature, 1988, 332:83-85.
Kishimoto, “The Biology of Interleukin-6,”Blood, 1989, 74:1-10.
Klein et al., “Paracrine Rather Than Autocrine Regulation of Myeloma-Cell Growth and Differentiation by Interleukin-6,”Blood, 1989, 73(2):517-526.
Klein et al., “Inhibition IL-6 in Human Multiple Myeloma,”Curr. Topics Microbiol. Immunol., 1992, 182:237-244.
Kyle, “Newer Approaches to the Management of Multiple Myeloma,”Cancer, 1993, 72(11):3489-3494.
Kyle, ““Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-up,”Mayo Clin. Proc., 1993, 68:26-36.
Kyle and Greipp, “Smoldering Multiple Myeloma,”New Engl. J. Med., 1980, 302:1347-1349.
Kyle and Lust, “Monoclonal Gammopathies of Undetermined Significance,”Sem. Hematol., 1989, 26(3):176-200.
Lacy et al., “Comparison of Interleukin-1β Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma,”Blood, 1999, 93:300-305.
Lust and Donovan, “The Role of Interleukin-1β in the Pathogenesis of Multiple Myeloma,”Hemagology/Oncology Clinics of North America, 1999, 13(6):1117-11125.
March et al., “Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs,”Nature, 1985, 315:641-647.
Nagata et al., “Interleukin 1 Autocrine Growth System in Human Multiple Myeloma,”Jpn. J. Clin. Oncol., 1991, 21:22-29.
Oken et al., “Comparison of Melphalan and Prednisone with Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Multiple Myeloma,”Cancer, 1997, 79:1561-1567.
Parker et al., “Cancer Statistics, 1996,”CA—A Cancer Journal for Clinicians, 1996, 46:5-27.
Portier et al., “In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma,”Eur. J. Immunol., 1991, 21:1759-1762.
Schwab et al., “Characterization of an Interleukin-6-Mediated Autocrine Growth Loop in the Human Multiple Myeloma Cell Line, U266,”Blood, 1991, 77(3):587-593.
Sleath et al., “Substrate Specificity of the Protease That Processes Human Interleukin-1β,”J. Biol. Chem., 1990, 265(24):14526-14528.
Tanihara et al., “A Synthetic Peptide Corresponding to
Donovan Kathleen A.
Lust John A.
Fish & Richardson P.C. P.A.
Hill Myron G.
Housel James
Mayo Foundation for Medical Education and Research
LandOfFree
IL1-β: a new target for myeloma therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL1-β: a new target for myeloma therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL1-β: a new target for myeloma therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3456279